Randomized Multicenter Double-Masked Placebo-Controlled Parallel Phase I/II Study to Determine the Safety and Exploratory Efficacy of Topical Fibrinogen Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs Host Disease
The purpose of this Phase 1/2 study is to compare the safety and tolerability of four times a day (QID) dosing of a non-preserved topical ocular drop formulation of 10 vol/vol % and 30 vol/vol % of FD hPL to vehicle control eye drops in patients with Dry Eye Disease (DED) secondary to Graft vs. Host Disease (GvHD).
100 Clinical Results associated with Cambium Medical Technologies LLC
0 Patents (Medical) associated with Cambium Medical Technologies LLC
100 Deals associated with Cambium Medical Technologies LLC
100 Translational Medicine associated with Cambium Medical Technologies LLC